Kailin Xu
The Affiliated Hospital oh Xuzhou Medical University · Xuzhou Medical University · The Affiliated Hospital of Xuzhou Medical University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Kailin Xu as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:53 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07070934 · CAR-T vs. Auto-SCT: Which Works Better for New Myeloma Patients?Xuzhou Medical University · not yet recruiting · Multiple Myeloma, Newly Diagnosed · study chair
- N/ANCT07070960 · A Study of Anti-BCMA CAR-T Therapy in Newly Diagnosed Myeloma Patients Who Are Transplant-ineligibleXuzhou Medical University · not yet recruiting · Multiple Myeloma, Newly Diagnosed · study chair
- Ph2NCT06963866 · Comparing ASCT Followed by Anti-BCMA CAR-T vs. ASCT Alone in NDMM Patients Eligible for ASCTXuzhou Medical University · not yet recruiting · Multiple Myeloma, Newly Diagnosed · study chair
- Ph1/Ph2NCT06196255 · Safety and Efficacy of Anti-FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM)Xuzhou Medical University · recruiting · Multiple Myeloma · study chair
- Ph1/Ph2NCT06132711 · Safety and Efficacy of APRIL-BAFF-Bicephali CAR-T in Relapsed, Refractory Multiple MyelomaXuzhou Medical University · recruiting · Multiple Myeloma · study chair
- Ph1/Ph2NCT06125652 · Administration of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)Xuzhou Medical University · recruiting · Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse · study chair
- Early Ph1NCT05744440 · Safety and Efficacy of Allogenic NK Cells in Combination With Chemotherapy in the Treatment of r/r AML After Allo-HSCTXuzhou Medical University · unknown · Acute Myeloid Leukemia · principal investigator
- Early Ph1NCT05739227 · Safety and Efficacy of Allogenic CD19-CAR-NK Cells in Treatmenting r/r B-cell Hematologic MalignanciesXuzhou Medical University · unknown · Acute Lymphoblastic Leukemia, B-cell Lymphoma, Chronic Lymphocytic Leukemia · principal investigator
- Ph2NCT05509530 · Safety and Efficacy of Anti-BCMA/GPRC5D CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma(rr/MM)Xuzhou Medical University · unknown · Multiple Myeloma · principal investigator
- Ph1/Ph2NCT05488132 · Administration of Anti-siglec-6 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)Xuzhou Medical University · unknown · Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse · principal investigator
- Ph1NCT04814004 · Clinical Study of CAR-iNKT Cells in the Treatment of Relapsed/Refractory/High-risk B-cell TumorsKai Lin Xu; Jun Nian Zheng · unknown · Acute Lymphoblastic Leukemia, B-cell Lymphoma, Chronic Lymphocytic Leukemia · study chair
- Ph1/Ph2NCT02794961 · CD22 Targeting CAR-T Therapy Against B Cell Hematological MalignanciesKai Lin Xu; Jun Nian Zheng · unknown · Recurrent or Refractory B Cell Malignancy · principal investigator
- Ph1/Ph2NCT02782351 · Humanized CAR-T Therapy for Treatment of B Cell MalignancyKai Lin Xu; Jun Nian Zheng · unknown · Leukemia, Lymphocytic, Chronic, B-Cell · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:53 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:53 UTC. The ranking covers the 200 most relevant of 397 PubMed records, and a shared surname and initials can bring in a namesake. All 397 on PubMed
- Five-Year Outcomes of Transcatheter or Surgical Aortic-Valve Replacement.N Engl J Med · 2020689 citationsRCR 39.1
- Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer.Nat Med · 1996595 citationsRCR 12.6
- Unmutated and mutated chronic lymphocytic leukemias derive from self-reactive B cell precursors despite expressing different antibody reactivity.J Clin Invest · 2005275 citationsRCR 5.0
- Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial.Circulation · 2013269 citationsRCR 9.3
- Contrast-induced acute kidney injury after primary percutaneous coronary intervention: results from the HORIZONS-AMI substudy.Eur Heart J · 2014209 citationsRCR 8.2
- 200 citationsRCR 9.5
- Clinical implications of new-onset left bundle branch block after transcatheter aortic valve replacement: analysis of the PARTNER experience.Eur Heart J · 2014194 citationsRCR 7.3
- Incidence, predictors, and prognostic impact of late bleeding complications after transcatheter aortic valve replacement.J Am Coll Cardiol · 2014193 citationsRCR 6.2
- Structural Deterioration of Transcatheter Versus Surgical Aortic Valve Bioprostheses in the PARTNER-2 Trial.J Am Coll Cardiol · 2020189 citationsRCR 10.7
- 179 citationsRCR 9.9